Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

#112: BIO's Rich Masters on the Future of Biotech and the International Convention

Jun 1, 20231 hr 15 minAudio

Navigating the biotech industry's rapid advancements and complex regulations can be daunting. High-stakes investments and the pressure to innovate further add to the challenge. Rich Masters, the CMO of BIO (Biotechnology Innovation Organization), is a seasoned expert in this field. His role in organizing the BIO International Convention and his extensive industry experience equips him with unique insights to tackle these challenges. In this fantastic podcast episode, we delve into: 🔬 The behind-the-scenes experience of organizing and attending the BIO International Convention 2022 in San Diego. 🔬 Rich's journey to the helm of BIO as CMO and his vision for the organization. 🔬 The meticulous preparations for the upcoming BIO International Convention 2023 in Boston, anticipated to be a landmark event in the biotech calendar. 🔬 The innovative features and services introduced for the BIO International Convention 2023, including the BIO Podcast series and the BIO News platform. 🔬 Rich's perspective on the future of the biotech industry, discussing potential challenges and opportunities for 2024 and beyond. 💡 LINKS TO MORE CONTENT Youtube Christian Soschner: Rich Masters 📖 Memorable Quotes: (13:50) "The majority of biomedical and drug innovation investments fail... This ecosystem is crucial and needs protection." (15:00) "Developing a drug is an expensive process... Without investment, the engine of innovation stalls, we don't see new drugs on the market." (16:38) "If you price fix these drugs, you are going to stop the cures of the future." (20:01) "What we're witnessing worldwide is an attack from socialist-minded groups against intellectual property, our only asset." (26:18)"Our main focus may be on Washington, but we work closely with our International Biotech Association based in Brussels. We have numerous international partners." (29:09) "As the next pandemic looms, the question is, do we want all drug development concentrated in one country, or a viable drug development market in the West?" (42:12) "We can't continue to stifle innovation and science and then expect to create the next generation of cures... we're eliminating entire classes of diseases." (44:10) "Biotechnology provides the solution for eliminating food insecurity, transitioning from fossil fuels to green energy sources, and ending disease... we need to establish policies that encourage, rather than stifle, innovation." ⏰ Timestamps: (03:45) - [Recap: BIO Convention Collaboration Success] (05:18) - [BIO Event Excellence: Future Planning Insights] (10:36) - [Inside BIO: CMO's Role & Event Portfolio] (17:05) - [Decoding Biomedical Investment Ecosystem] (20:31) - [Behind BIO Conventions: Passion & Effort] (22:15) - [Biotech Investment: Price Fixing & IP Challenges] (27:41) - [Capital Formation in Biotech: Navigating Economic Shifts] (29:33) - [Global Biotech Politics: Washington & Brussels Focus] (32:24) - [Future of Drug Development: Market Shift Navigation] (35:32) - [BIO 1-1 Partnering: Revolutionizing Biotech Startup Growth] (42:54) - [Policy Impact & Transition to Physical Conventions] (47:25) - [Biotech Solutions: Hunger, Climate, Disease] (51:32) - [Bio Convention Revolution: Aggressive Marketing Strategy] (55:57) - [Middle East Evolution in Global Innovation Scene] (59:30) - [Balancing Attendee Expectations: The Art & Challenges] (01:03:32) - [Diverse Voices: Crafting an Inclusive BIO Speaker Line-up] Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode